Showing 3041-3050 of 5771 results for "".
- Harrow Enters into 340B Prime Vendor Program Contract with Apexus for Iheezohttps://modernod.com/news/harrow-enters-into-340b-prime-vendor-program-contract-with-apexus-for-iheezo/2482349/Harrow announced that as of July 1, 2024, it has entered into an agreement with Apexus to make Iheezo (chloroprocaine hydrochloride ophthalmic gel) 3% and other Harrow products available through its 340B Prime Vendor Program. Iheezo, indicated for ocular anesthesia, is a low-visc
- EyeSouth Partners Unveils Clinical Research Divisionhttps://modernod.com/news/eyesouth-partners-unveils-clinical-research-division/2482345/EyeSouth Partners has announced the expansion of
- CDRH Expands TAP Program to Include Ophthalmic Deviceshttps://modernod.com/news/cdrh-expands-tap-program-to-include-ophthalmic-devices/2482344/Jeff Shuren, MD, director of the FDA’s Center for Devices and Radiological Health (CDRH), announced the continued expansion of the Total Product Life Cycle (TPLC) Adv
- PharmAbcine Advances Phase 1 Clinical Trial of PMC-403 for nAMDhttps://modernod.com/news/pharmabcine-advances-phase-1-clinical-trial-of-pmc-403-for-namd/2482343/PharmAbcine, Inc., a South Korea-based clinical-stage developer of medical therapeutics, announced the Safety Review Committee (SRC) approval of single 3-mg dose for the third cohort in phase 1 clinical trial of PMC-403, the company&rsquo
- FDA Approves Genentech’s Vabysmo Prefilled Syringe for AMD, DME, and RVOhttps://modernod.com/news/genentechs-vabysmo-prefilled-syringe-approved-by-fda-for-amd-dme-and-rvo/2482342/Genentech announced FDA approval of Vabysmo (faricimab-svoa) 6.0 mg single-dose prefilled syringe (PFS) for use in the treatment of wet age-related macular degeneration (AMD), diabetic macular edema (DME), and macular edema after retinal vein occlusion (RVO). The company advised that Vabysmo
- Beacon Therapeutics Raises Funds to Advance Development of Its Ophthalmic Gene Therapieshttps://modernod.com/news/beacon-therapeutics-raises-funds-to-advance-development-of-its-ophthalmic-gene-therapies/2482341/Beacon Therapeutics announced it has raised $170 million in Series B funding, which will be used to support the continued clinical development of Beacon’s lead asset, AGTC-501, for X-linked retinitis pigmentosa (XLRP; laruparetigene zovaparvovec) and generate phase 1/2 clinical trial d
- J-Code for Glaukos’ iDose TR Becomes Activehttps://modernod.com/news/cms-j-code-for-glaukos-idose-tr-becomes-active/2482340/Glaukos announced that the CMS Healthcare Common Procedure Coding System’s J-code—J7355—for the company’s iDose TR is effective. The J-code provides patient access and streamlines the coverage and payment process as Glaukos advances its commercial launch of the treatment.<
- NurExone’s Exosome-Based Exopten Therapy Studied to Treat Glaucomahttps://modernod.com/news/nurexones-exosome-based-exopten-therapy-studied-to-treat-glaucoma/2482339/NurExone Biologic announced a preclinical study to explore the potential of one of the company’s exosome-based therapies, Exopten, in regenerating damaged optic nerves. The study is NurExone Biologic’s latest step in expanding potential clinical indications for its exosome-loaded
- Alcon Completes Acquisition of Belkin Visionhttps://modernod.com/news/alcon-completes-acquisition-of-belkin-vision/2482338/Alcon announced the closing of its acquisition of Belkin Vision, which was initially reported in May 2024. The acquisition involved a total upfront
- Vabysmo Receives CHMP Recommendation for RVO Indicationhttps://modernod.com/news/roches-vabysmo-gets-chmp-recommendation-for-rvo-indication/2482337/Roche announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for the extension of Vabysmo (faricimab) marketing authorization to include the treatment of visual impairment caused by macular edema secondary to retin